Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01770691
Recruitment Status : Completed
First Posted : January 18, 2013
Results First Posted : January 16, 2015
Last Update Posted : January 16, 2015
Information provided by (Responsible Party):
Assuta Hospital Systems

Brief Summary:

Stress urinary incontinence (SUI) is most prevalent among women. SUI is characterized by loss of urine from increased abdominal pressures caused by coughing, laughing, sneezing, running, lifting or walking. SUI cause women to avoid routine physical activities, thus detracting significantly from their quality of life.

The purpose of this study is to evaluate the performance of new designs of the TIPI device, a conservative, disposable, treatment for temporary management of SUI.

Condition or disease Intervention/treatment Phase
Stress Urinary Incontinence Device: TIPI vaginal pessary Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence
Study Start Date : September 2007
Actual Primary Completion Date : June 2009
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: TIPI vaginal pessary
Each subject will use different SMD'S (Slightly modified designs) of the TIPI vaginal pessary. Not all subjects will use all types of SMD's
Device: TIPI vaginal pessary
TIPI vaginal pessary G3 model, and TIPI SMD's

Primary Outcome Measures :
  1. Mean Percentage of Pad Weight Gain (PWG) Change [ Time Frame: up to 8 hours of use ]

    All eligible subjects underwent a 3-day Pad period to establish baseline Average PWG. During this period, pre-weighed pads were worn for 8 hours a day and subjects were asked to perform predefined physical activities and drink a certain amount of liquid, daily. Pads were collected and weighed in the clinic to determine baseline urine leakage. Subjects then used SMDs or the cleared TIPI (G3) with pads for up to 8 hours. The average PWG tests results with the TIPI devices were compared to the average PWG 8 hrs test without the device and were presented as percentages.

    The efficacy endpoint for the study was mean percent change of PWG using a certain device compared to the values obtained at the baseline period, as calculated by the following formula:

    % Reduction = 1-(Device/Baseline )*100

    Where, Device = the average pad weight gain (PWG) during device usage. Baseline = the average pad weight gain (PWG) during the days of baseline period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females aged 18 to 60 years
  • Had ≥ 1 deliveries
  • Suffering from genuine stress urinary incontinence confirmed by urodynamic testing (Urodynamic stress urinary incontinence) and normal voiding without abnormal residual urine
  • Baseline PWG (no usage of TIPI device) ≥ 6gr/8hrs
  • Average reduction of urinary incontinence of at least 70% following 3 days usage of the cleared TIPI G3 device
  • The patient has the ability to understand the nature of the study and give her consent by signing a written informed consent form.
  • Successful experience with the use of vaginal tampons
  • Willing to undergo urodynamic investigation
  • Normal pap smear within past 24 months
  • Patient is able and agrees to arrive to the study site area for a period of about 4-6 hours during 6-12 non consequent study days.

Exclusion Criteria:

  • Patient is pregnant, or suspected to be pregnant or is planning to be pregnant during the course of the study
  • Patients with present or suspected urinary infection
  • Patients with present or suspected vaginal infection
  • Severely atrophic vagina
  • Women who did not manage to insert a vaginal tampon, for any reason, in the past
  • Abnormal vaginal bleeding
  • Patient is currently participating in another clinical study that may directly or indirectly affect the results of this study
  • Was/is being treated for urinary incontinence by other means such as medications, surgical intervention etc. that might influence study results
  • Vaginal wall prolapse of any type reaching the level of the introitus (grade 2)
  • Co-morbid condition(s) that could limit the patient's ability to participate in the study, or impact the scientific integrity of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01770691

Urodynamic Unit, Assuta Medical Centers
Tel Aviv, Israel
Sponsors and Collaborators
Assuta Hospital Systems
Principal Investigator: Elan Ziv, MD, OBGYN Urodynamic Unit, Assuta Medical Centers, Tel Aviv, Israel

Responsible Party: Assuta Hospital Systems Identifier: NCT01770691     History of Changes
Other Study ID Numbers: TIPI 004
First Posted: January 18, 2013    Key Record Dates
Results First Posted: January 16, 2015
Last Update Posted: January 16, 2015
Last Verified: January 2015

Additional relevant MeSH terms:
Urinary Incontinence
Urinary Incontinence, Stress
Urination Disorders
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Behavioral Symptoms
Elimination Disorders
Mental Disorders